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Abstract
Background: Non-gastrointestinal stromal tumor soft-tissue sarcomas (non-GIST STSs) constitute a heterogeneous
group of tumors with poor prognosis. Fibroblast growth factor 2 (FGF2) and fibroblast growth factor receptor-1
(FGFR-1), in close interplay with platelet-derived growth factor-B (PDGF-B) and vascular endothelial growth factor
receptor-3 (VEGFR-3), are strongly involved in angiogenesis. This study investigates the prognostic impact of FGF2
and FGFR-1 and explores the impact of their co-expression with PDGF-B and VEGFR-3 in widely resected tumors
from non-GIST STS patients.
Methods: Tumor samples from 108 non-GIST STS patients were obtained and tissue microarrays were constructed
for each specimen. Immunohistochemistry was used to evaluate the expressions of FGF-2, FGFR-1, PDGF-B and
VEGFR-3.
Results: In the multivariate analysis, high expression of FGF2 (P = 0.024, HR = 2.2, 95% CI 1.1-4.4) and the
co-expressions of FGF2 & PDGF-B (overall; P = 0.007, intermediate; P = 0.013, HR = 3.6, 95% CI = 1.3-9.7, high;
P = 0.002, HR = 6.0, 95% CI = 2.0-18.1) and FGF2 & VEGFR-3 (overall; P = 0.050, intermediate; P = 0.058, HR = 2.0,
95% CI = 0.98-4.1, high; P = 0.028, HR = 2.6, 95% CI = 1.1-6.0) were significant independent prognostic indicators
of poor disease-specific survival.
Conclusion: FGF2, alone or in co-expression with PDGF-B and VEGFR-3, is a significant independent negative
prognosticator in widely resected non-GIST STS patients.
Introduction
Soft-tissue sarcomas (STSs) constitute a group of
tumors of mesenchymal lineage, comprising over 50 his-
tological entities [1]. The incidence is low and the leth-
ality is high. With an estimate of 10 000 new cases and
nearly 4 000 related deaths in the US in 2010, STSs
remain one of the most aggressive types of cancer [2].
Current STS treatment comprises wide resection of
the primary tumor with supplementary radiotherapy to
those with high-grade lesions [3-5]. Since the use of
chemotherapy is a challenge in adult STS, due to con-
troversial efficacy [6], good prognostic and predictive
indicators are highly warranted to help select patients
for different types of chemotherapy treatments.
Fibroblast growth factors (FGFs) are heparin binding
growth factors and as of today there are 18 FGFs and 4
fibroblast growth factor receptors (FGFRs) identified in
humans [7]. The most extensive research in this field
has been done on FGF2 (also known as basic fibroblast
growth factor; bFGF), a growth factor primarily binding
FGFR-1 [7]. FGF2 is a known promoter of angiogenesis
and lymphangiogenesis [8]. Further, FGF2 stimulates
cell growth and migration, but also, in some cases,
differentiation [8].
Compared to healthy controls, plasma FGF2 levels, in
sarcoma patients, is reported to be elevated. In contrast,
low plasma FGF2 levels prior to surgery have been asso-
ciated with an increased risk of recurrence [9-12]. FGF2
presence has also been confirmed in studies of sarcoma
cell-lines [13].
FGF2 has been implicated as a player in different
angiogenic and lymphangiogenic pathways [8]. Nissen et
al. reported a reciprocal relationship between FGF2 and
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corresponding receptors [14]. Kubo et al. found FGF2
induced lymphangiogenesis to be blocked by vascular
endothelial growth factor receptor-3 (VEGFR-3) inhibi-
tors [15]. Further, in a study on human umbilical cord
endothelial cells grown in the presence of VEGF-A,
Welti et al. found FGF2 to rescue angiogenesis in pre-
sence of the VEGFR inhibitor Sunitinib
® [16].
We have previously reported on the prognostic impact
of the PDGFs and VEGFs and their receptors in this
cohort of non-GIST STS patients [17,18]. The aim of
this study was to investigate the prognostic impact of
FGF2 and FGFR-1 expression, and their co-expressions
with PDGF-B and VEGFR-3, in widely resected non-
GIST STS patients.
Patients and methods
Patients and Clinical Samples
Primary tumor tissue from anonymized patients diag-
nosed with non-GIST STS at the University Hospital of
North-Norway and the Hospitals of Arkhangelsk county,
Russia, from 1973 through 2006, were collected. In total
496 patients were registered from the hospital databases.
Of these, 388 patients were excluded from the study
because of: missing clinical data (n = 86), inadequate
paraffin-embedded fixed tissue blocks (n = 161) or non-
wide resection margins (n = 141). Thus 108 patients
with complete medical records, adequate paraffin-
embedded tissue blocks and wide resection margins
were eligible.
This report includes follow-up data as of September
2009. The median follow-up was 68.4 (range 0.5-391.7)
months. Complete demographic and clinical data were
collected retrospectively. Formalin-fixed and paraffin-
embedded tumor specimens were obtained from the
archives of the Departments of Pathology at the Univer-
sity Hospital of North-Norway and the Hospitals of
Arkhangelsk County, Russia. The tumors were graded
according to the French Fédération Nationale des cen-
tres de Lutte Contre le Cancer (FNCLCC) system and
histologically subtyped according to the World Health
Organization guidelines [1,19]. Wide resection margins
were defined as wide local resection with free micro-
scopic margins or amputation of the affected limb or
organ.
Microarray construction
All sarcomas were histologically reviewed by two trained
pathologists (S. Sorbye and A. Valkov) and the most
representative areas of tumor cells (neoplastic mesench-
ymal cells) were carefully selected and marked on the
hematoxylin and eosin (H/E) slide and sampled for the
tissue microarray (TMA) blocks. The TMAs were
assembled using a tissue-arraying instrument (Beecher
Instruments, Silver Springs, MD). The Detailed metho-
dology has been previously reported [20,21]. Briefly, we
used a 0.6 mm diameter stylet, and the study specimens
were routinely sampled with four replicate core samples
from different areas of neoplastic tissue. Normal tissue
from the patients was used as staining control.
To include all core samples, 12 TMA blocks were
constructed. Multiple 5-μm sections were cut with a
Micron microtome (HM355S) and stained by specific
antibodies for immunohistochemistry (IHC) analysis.
Immunohistochemistry
The applied antibodies were subjected to in-house
validation by the manufacturer for IHC analysis on par-
affin-embedded material. The antibodies used in the
study were FGF2 (rabbit polyclonal; AB1458; Chemicon;
1:200) and FGFR-1 (rabbit polyclonal; sc-121; Santa
Cruz; 1:50). The IHC procedures for PDGF-B and
VEGFR-3 have been previously described [17,18].
Sections were deparaffinized with xylene and rehy-
drated with ethanol. Antigen retrieval was performed by
placing the specimen in 0.01 M citrate buffer at pH 6.0
and exposed to microwave heating of 10 minutes at 250
W (FGF2) or heated by pressure boiler of 2 minutes
(FGFR-1). The DAKO EnVision + System-HRP (DAB)
kit was used as endogen peroxidase blocking. As nega-
tive staining controls, the primary antibodies were
replaced with the primary antibody diluent. Primary
antibodies were incubated for 30 minutes (FGF2) or 60
minutes (FGFR-1) in room temperature. The kit DAKO
EnVision + System-HRP (DAB) was used to visualize
the antigens. This was followed by application of liquid
diaminobenzidine and substrate-chromogen, yielding a
brown reaction product at the site of the target antigen.
Finally, all slides were counter-stained with hematoxylin
to visualize the nuclei. For each antibody, included
negative staining controls, all TMA staining were per-
formed in a single experiment.
Scoring of immunohistochemistry
The ARIOL imaging system (Genetix, San Jose, CA) was
used to scan the slides of antibody staining of the
TMAs. The slides were loaded in the automated slide
loader (Applied Imaging SL 50) and the specimens were
scanned at low resolution (1.25×) and high resolution
(20×) using the Olympus BX 61 microscope with an
automated platform (Prior). Representative and viable
tissue sections were scored manually on the computer
screen semi-quantitatively for cytoplasmic staining. The
dominant staining intensity was scored as: 0 = negative;
1 = weak; 2 = intermediate; 3 = strong. All samples
were anonymized and independently scored by two
trained pathologists (A. Valkov and S. Sorbye). When
a s s e s s i n gav a r i a b l ef o rag i v e nc o r e ,t h eo b s e r v e r sw e r e
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come. Mean score for duplicate cores from each indivi-
dual was calculated separately.
High expression in tumor cells was defined as score ≥
2( F G F 2a n dF G F R - 1 )( F i g u r e1 ) .T h ep r e v i o u s l yp u b -
lished cut-off values for PDGF-B and VEGFR-3 (≥ 1.5)
were used to estimate the co-expressions with FGF2 and
FGFR-1 [17,18].
Statistical Methods
All statistical analyses were done using the statistical
package SPSS (Chicago, IL), version 16. The IHC scores
from each observer were compared for interobserver
reliability by use of a two-way random effect model with
absolute agreement definition. The intraclass correlation
coefficient (reliability coefficient) was obtained from
these results. The Chi-square test and Fishers Exact test
were used to examine the association between molecular
marker expression and various clinicopathological
p a r a m e t e r s .U n i v a r i a t ea n a l y s e sw e r ed o n eu s i n gt h e
Kaplan-Meier method, and statistical significance
between survival curves was assessed by the log-rank
test. Disease-specific survival (DSS) was determined
from the date of diagnosis to the time of cancer related
death. To assess the independent value of different
pretreatment variables on survival, in the presence of
other variables, multivariate analyses were carried out
using the Cox proportional hazards model. Only vari-
ables of significant value from the univariate analyses
were entered into the Cox regression analysis. Probabil-
ity for stepwise entry and removal was set at .05 and
.10, respectively. The significance level used for all
statistical tests was P < 0.05.
Ethical clearance
The National Data Inspection Board and The Regional
Committee for Research Ethics approved the study.
Results
Clinopathological Variables
The clinopathological variables are summarized in
Table 1. The median age was 57 (range 0-86) years, 56%
were female, 73 patients were Norwegian and 35 Russian.
The Non-GIST STSs comprised 108 tumors including
angiosarcoma (n = 5), fibrosarcoma (n = 8), leiomyosar-
coma (n = 34), liposarcoma (n = 13), pleomorphic sar-
coma (n = 29), neurofibrosarcoma/malignant peripheral
nerve sheath tumor (MPNST, n = 5), rhabdomyosarcoma
(n = 6), synovial sarcoma (n = 6) and unspecified
sarcoma (n = 2). The tumor origins were distributed as
follows: 43% extremities, 19% trunk, 7% retroperitoneal,
4% head/neck and 28% visceral. In addition to surgical
resection, 6 patients received both radio-and chemother-
apy, 23 patients received chemotherapy alone and 15
patients received radiotherapy alone.
Interobserver variability
Interobserver scoring agreement was tested for FGF2
and FGFR-1. The intraclass correlation coefficients were
0.80 for FGF2 (P < 0.001) and 0.93 for FGFR-1 (P <
0.001), indicating good reproducibility between the
investigating pathologists.
Expression of FGF2/FGFR-1 and their Correlations
FGF2/FGFR-1 expression was localized in the cytoplasm
of tumor cells.
FGF2 did not correlate with the clinical variables while
low FGFR-1 expression correlated with small tumor size
(low expression; < 50 mm 44%, 50-100 mm 34%, > 100
mm 22%, P = 0.005).
Univariate Analyses
Table 1 summarizes the prognostic impact of the clino-
pathological variables. Patient nationality (P < 0.001),
malignancy grade (P < 0.001), tumor depth (P = 0.009)
and metastasis at diagnosis (P < 0.001) were prognostic
indicators of DSS.
The influence on DSS by FGF2 and FGFR-1 are given
in Table 2 and Figure 2 panels A and B. High
Figure 1 IHC analysis of TMA of non-gastrointestinal stromal
tumor soft-tissue sarcoma representing different scores for
tumor cell FGF2 and FGFR-1. (A) Tumor cell FGF2 low score in
Fibrosarcoma; (B) Tumor cell FGF2 high score in undifferentiated
pleomorphic sarcoma; (C) Tumor cell FGFR-1 low score in
undifferentiated pleomorphic sarcoma; (D) Tumor cell FGFR-1 high
score in undifferentiated pleomorphic sarcoma. Abbreviations: FGF,
fibroblast growth factor; FGFR, fibroblast growth factor receptor; IHC,
immunohistochemistry; TMA, tissue microarray.
Kilvaer et al. Journal of Translational Medicine 2011, 9:104
http://www.translational-medicine.com/content/9/1/104
Page 3 of 8Table 1 Prognostic clinicopathological variables as predictors for disease-specific survival in patients with completely
resected non-gastrointestinal stromal tumor soft-tissue sarcomas (univariate analyses, log rank test; multivariate
analysis, Cox regression analysis)
Univariate analyses Multivariate analysis
Characteristics Patients
(n)
Patients
(%)
Median
survival
(months)
5-Year
survival
(%)
P HR 95% CI P
Age
≤ 20 years 7 7 NR 57 0.960
21-60 years 55 51 NR 64
> 60 years 46 43 NR 60
Gender
Male 47 44 NR 74 0.054
Female 61 56 127 53
Patient nationality
Norwegian 73 68 NR 73 < 0.001 1.000
Russian 35 32 22 38 2.777 1.457-5.292 0.002
Histological entity
Pleomorphic sarcoma 29 27 54 50 0.127
Leiomyosarcoma 34 32 68 53
Liposarcoma 13 12 NR 92
Fibrosarcoma 8 7 NR 88
Angiosarcoma 5 5 NR 60
Rhabdomyosarcoma 6 6 NR 67
MPNST 5 5 NR 80
Synovial sarcoma 6 6 59 80
Sarcoma NOS 2 2 NR 100
Tumor localization
Extremities 46 43 NR 66 0.735
Trunk 21 19 NR 60
Retroperitoneum 7 7 NR 71
Head/Neck 4 4 NR 75
Visceral 30 28 63 53
Tumor size
≤ 5 cm 40 37 NR 75 0.262
5-10 cm 46 43 NR 53
>1 0c m 2 0 1 8 N R 6 0
Missing 2 2
Malignancy grade 0.015*
1 32 30 NR 90 < 0.001 1.000
2 36 33 NR 61 3.808 1.084-13.380 0.037
3 40 37 32 39 5.937 1.721-20.481 0.005
Tumor depth
Superficial 12 11 ** ** 0.009 ** ** **
Deep 96 89 57
Metastasis at diagnosis
No 97 90 218 66 < 0.001 1.000
Yes 11 10 8 27 4.689 2.004-10.972 < 0.001
Chemotherapy
No 79 73 NR 65 0.234
Yes 29 27 120 55
Radiotherapy
No 87 81 NR 63 0.375
Yes 21 19 NR 57
Abbreviations: NR, not reached; MPNST, malignant peripheral nerve sheath tumor; NOS, not otherwise specified; *, overall significance as a prognostic factor; **all
cases were censored.
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ciated with a poor prognosis.
Multivariate Cox Proportional Hazards Analysis
Table 1 and 2 summarizes the results of the multivariate
analysis of clinopathological variables and marker
expression, respectively. Russian nationality (P = 0.002),
high malignancy grade (P = 0.015), metastasis at diagno-
sis (P < 0.001) and high FGF2 expression (P = 0.024,
HR = 2.203, 95% CI 1.11-4.38) were significant indepen-
dent negative indicators of DSS.
Co-expressions
In univariate analyses, the co-expressions of FGF2 &
PDGF-B (P = 0.011) and FGF2 & VEGFR-3 (P = 0.042)
were significant prognostic indicators of DSS (Table 2).
In the multivariate analyses, high expression of FGF2 &
PDGF-B was, when compared to low expression, a sig-
nificant independent prognostic indicator of poor DSS
(HR = 6.0, 95% CI = 1.966-18.132, P = 0.002). High
expression of FGF2 & VEGFR-3 (HR = 2.6, 95% CI =
1.106-6.038, P = 0.028) was also a significant indepen-
dent prognosticator (Table 2, Figure 2 panels C and D).
Figure 3 shows proposed actions of expressed FGF2,
PDGF-B and VEGFRs in non-GIST STSs.
Discussion
In the study presented herein we have observed high
tumor expression of FGF2 and the co-expressions of
FGF2 & PDGF-B and FGF2 & VEGFR-3 to be signifi-
cant, independent and unfavorable prognostic indicators
of DSS in non-GIST STS patients with wide resection
Table 2 Tumor expression of FGF2, FGFR-1 and the co-expressions of FGF2 & PDGF-B and FGF2 & VEGFR-3 and their
prediction for disease-specific survival in patients with completely resected non-gastrointestinal stromal tumor soft-
tissue sarcomas (univariate analyses, log rank test; multivariate analysis, Cox regression analysis)
Univariate analyses Multivariate analysis
Marker expression Patients
(n)
Patients
(%)
Median
survival
(months)
5-Year
survival
(%)
P HR 95% CI P
FGF2
Low 75 69 NR 68 0.048 1.000
High 30 28 54 50 2.203 1.108-4.379 0.024
Missing 3 3
FGFR-1
Low 78 72 NR 61 0.830
High 28 26 NR 62
Missing 2 2
FGF2 & PDGF-B 0.007*
Low 27 25 NR 81 0.011 1.000
Intermediate 52 48 NR 59 3.569 1.311-9.715 0.013
High 25 23 45 48 5.971 1.966-18.132 0.002
Missing 4 4
FGF2 & VEGFR-3 0.050*
Low 51 47 NR 70 0.042 1.000
Intermediate 35 32 120 56 1.999 0.978-4.087 0.058
High 16 15 45 46 2.584 1.106-6.038 0.028
Missing 6 6
FGFR-1 & PDGF-B
Low 26 24 NR 75 0.061
Intermediate 56 52 120 55
High 23 21 NR 58
Missing 3 3
FGFR-1 & VEGFR-3
Low 57 53 NR 66 0.344
Intermediate 29 27 120 59
High 18 17 63 52
Missing 4 4
Abbreviations: FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; NR, not reached; PDGF, platelet-derived growth factor; VEGFR, vascular
endothelial growth factor receptor; *overall significance as prognostic factor.
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1 in STS and no previous studies have reported on the
co-expressions with PDGF-B and VEGFR-3. To our
knowledge this is the first evaluation of these pathways
in non-GIST STSs.
We have previously reported on the prognostic impact
o fP D G F sa n dV E G F si nt h i sp a t i e n tc o h o r t[ 1 7 , 1 8 ] .I n
the previous investigationsw ef o u n dt h ep r o g n o s t i c
impact of these growth factors and their pathways to be
dependent on wide resection margins. Without wide
resection margins, the prognosis is poor with only 30%
5-year survivors and angiogenic markers could not dis-
tinguish between prognostic groups.
Our results are, by large, consistent with previously
published data on FGF2 in STSs. Graeven et al. reported
that FGF2 levels in serum of STS patients were elevated
in comparison to that of controls [12]. Yoon et al., using
microarray techniques, found FGF2 gene-expression to
be significantly higher in STS patient tissue samples
compared to healthy controls [11]. We found high FGF2
expression in tumor to be a significant independent
negative prognostic marker in non-GIST STS patients
with wide resection margins.
There are several ways in which FGF2 can promote
non-GIST STS development, as illustrated in Figure 3.
Endothelial cells treated with FGF2 in vitro and in vivo
form tubes, proliferate and are induced to migrate [8].
Further, FGF2 has also been associated with extracellular
matrix remodeling, pivotal in angiogenesis/lymphangio-
genesis, through increased release and expression of
matrix metallo-proteinases and urokinase-like plasmino-
gen activator [8]. In addition, FGF2 has recently been
shown to rescue PDGF-B transfected cells undergoing
Imatinib
® induced apoptosis [22] and to sustain the
angiogenic profile of human umbilical cord cells grown
with VEGF-A in the presence of the VEGFR inhibitor
Sunitinib
® [16]. Angiogenesis is one of the hallmarks of
cancer and adaptation of an angiogenic profile is one of
the deciding steps in carcinogenesis [23]. These latter
results indicate that the FGF pathway contributes to the
redundancy observed when targeting angiogenesis in can-
cer (Figure 3b). In addition, FGF2 could function as a
growth factor on the tumor cells in a paracrine/autocrine
fashion, activating intracellular pathways and ultimately
leading cells to proliferate, avoid apoptosis or become
insensitive to antigrowth signals (Figure 3a) [8,24].
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Figure 2 Disease-specific survival curves for (A) FGF2; (B) FGFR-
1; (C) FGF2 & PDGF-B; (D) FGF2 & VEGFR-3. Abbreviations: FGF,
fibroblast growth factor; FGFR, fibroblast growth factor receptor;
PDGF, platelet-derived growth factor; VEGFR, vascular endothelial
growth factor receptor.
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Figure 3 Proposed mechanisms of stimulation of growth,
angiogenesis and motility in non-gastrointestinal stroma
tumor soft-tissue sarcomas expressing FGF2, PDGF-B and
VEGFR-3. (A) Paracrin and/or autocrin stimulation of cancer cells
leading to activation of intracellular pathways and subsequently
survival benefits; (B) FGF2 stimulating angiogenesis through
recruitment of endothelial cells and increasing release of MMPs and
uPa leading to ECM degradation and remodeling thus enabling
tumor cell expansion and motility, PDGF-B recruiting VSMCs and
stimulating pericyte coverage of newly formed vessle; Abbreviations:
ECM, extracellular matrix; FGF, fibroblast growth factor; FGFR,
fibroblast growth factor receptor; PDGF, platelet-derived growth
factor; PDGFR, platelet-derived growth factor receptor; MMP, matrix-
metallo proteinase; uPa, urokinase-like plasminogen activator; VEGF,
vascular endothelial growth factor; VEGFR, vascular endothelial
growth factor receptor.
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working as a chemotactic and proliferative agent on vas-
cular smooth muscle cells (VSMCs) and pericytes
[25-27]. Nissen et al. investigated the possibility of inter-
actions between the FGF2 and PDGF-B signaling path-
ways and found FGF2 and PDGF-B to synergistically
induce neovascularization in murine fibrosarcomas [14].
In our cohort, patients who expressed high intensity
staining of PDGF-B and FGF2 had HR’so f3 . 9o r2 . 2
[18], respectively, in comparison to those expressing low
intensity staining. Examining the co-expression of FGF2
& PDGF-B revealed a HR of 6.0 for the high-high
expression group (Table 2), indicating an additive or
p o s s i b l yas y n e r g e t i ce f f e c to ft h e s ep a t h w a y si nn o n -
GIST STSs.
VEGFR-3 is classically associated with lymphangiogen-
esis, but has recently been linked to angiogenesis
[28,29]. Using the mouse corneal assay, Kubo et al.
found FGF2 induced angiogenesis to be blocked by
administration of VEGFR-3 inhibitors, indicating an
interaction between these pathways [15]. Previously, we
found non-GIST STS patients with wide resection mar-
gins expressing high intensity VEGFR-3 staining to have
a HR of 2.0 compared to those with low intensity stain-
ing [17]. For the co-expression of FGF2 & VEGFR-3 we
found a HR of 2.6 in the high-high expression group,
indicating a modest additive effect between these path-
ways in non-GIST STSs.
FGF2, PDGF-B and VEGFR-3 expression leads to acti-
vation of several different intracellular pathways includ-
ing PI3K, MEKK, SEK, PLCg and others. Further studies
to investigate the relative involvement of these pathways
in sarcoma angiogenesis development would be of great
interest. Players in these pathways could prove to be tar-
gets for novel therapeutic approaches both together with
cytokine binding antibodies and receptor blockers and
alone.
We have previously found FGF2 and the co-expres-
s i o n so fF G F 2&P D G F - Ba n dF G F 2&V E G F R - 3t ob e
poor independent prognosticators in an unselected large
non-small cell lung cancer cohort [30]. The finding of
similar results in cancers derived from different embryo-
nic cell-layers may indicate that tumor vasculogenesis as
a whole, or at least for certain mechanisms, are univer-
sal processes.
Conclusion
The angiogenic and lymphangiogenic systems have
redundant and synergetic properties making it difficult
to target these pathways with chemotherapy alone.
Nevertheless, we observed that high expression of FGF2
and the co-expressions of FGF2 & PDGF-B and FGF2 &
VEGFR-3 are significant independent negative prognos-
tic factors in widely resected non-GIST STS patients.
These results suggest that the angiogenic properties of
sarcomas are versatile and complex, hence multitargeted
antiangiogenic treatment could prove an interesting
approach in non-GIST STSs.
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